The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Sung Jae Shin - One of the best experts on this subject based on the ideXlab platform.
-
Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçet’s Disease Patients: Relation to Clinical Course
Diseases of the Colon & Rectum, 2006Co-Authors: Chang Hwan Choi, Sung Jae ShinAbstract:Purpose This study was designed to assess anti- Saccharomyces cerevisiae antibody positive rate in Behçet’s disease and intestinal Behçet’s disease and to evaluate whether anti- Saccharomyces cerevisiae antibody expression is associated with clinical findings at diagnosis and clinical course of intestinal Behçet’s disease. Methods One hundred six patients with intestinal Behçet’s disease, 30 patients with Behçet’s disease, and 45 healthy control subjects were included. Anti- Saccharomyces cerevisiae antibody was detected by indirect immunofluorescence assay. According to anti- Saccharomyces cerevisiae antibody expression, the various parameters at diagnosis, cumulative relapse rates, and cumulative probabilities of operation were analyzed. Results Anti- Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet’s disease, 3.3 percent in Behçet’s disease, and 8.8 percent in healthy control subjects. In patients with intestinal Behçet’s disease, age, gender, distribution of Behçet’s disease subtype, symptoms, laboratory tests, and colonoscopic findings at diagnosis were not different according to anti- Saccharomyces cerevisiae antibody expression. Cumulative probability of a first operation was significantly higher in anti- Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease than in anti- Saccharomyces cerevisiae antibody (−) intestinal Behçet’s disease: 44.8 and 17.2 percent at one year, and 53 and 24.3 percent at two years after diagnosis, respectively ( P = 0.006). The number of patients who underwent two or more operations was higher in anti- Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease than in anti- Saccharomyces cerevisiae antibody (−) intestinal Behçet’s disease (21.3 vs . 8.5 percent). The cumulative relapse rates were not different between the two groups. Conclusions Anti- Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet’s disease. Clinical findings at diagnosis and cumulative relapse rates of intestinal Behçet’s disease were not found to be associated with anti- Saccharomyces cerevisiae antibody expression. However, patients with anti- Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease were more likely to receive surgical treatment.
Shu-juan Dai - One of the best experts on this subject based on the ideXlab platform.
-
Mechanism of Adsorbing Cadmium in Electroplating Wastewater by Water-Washing Waste Saccharomyces cerevisiae
Advanced Materials Research, 2011Co-Authors: Shu-juan Dai, Dong-qin Zhou, De Zhou Wei, Shu Yong YangAbstract:The function mechanism of water-washing waste Saccharomyces cerevisiae and cadmium in electroplating wastewater was studied by desorption by washing experiment，chemiscal modification experiment and XPS analysis of water-washing Saccharomyces cerevisiae pre-adsorbing and post-adsorbing cadmium. The desorption by washing experiment result show that chemiscal adsorption is the main adsorption form; phsicalffunt chemiscal modification experiment result show –NH2 –COOH was important groups of water-washing Saccharomyces cerevisiae effecting on cadmium, XPS analysis result show that effect on water-washing Saccharomyces cerevisiae and cadmiun was not only on the surface but also in the cells.
-
Removing cadmium from electroplating wastewater by waste Saccharomyces cerevisiae
Transactions of Nonferrous Metals Society of China, 2008Co-Authors: Shu-juan Dai, Dezhou Wei, Dong-qin Zhou, Chunyun Jia, Yu-juan Wang, Wengang LiuAbstract:The appropriate condition and scheme of removing cadmium from electroplating wastewater were investigated by adsorption-precipitation method using waste Saccharomyces cerevisiae(WSC) as sorbent. Effect factors on biosorption of cadmium in cadmium-containing electroplating wastewater by waste Saccharomyces cerevisiae and precipitation process of waste Saccharomyces cerevisiae after adsorbing cadmium were studied. The results show that removal rate of cadmium is over 88% after 30 min adsorbing under the condition of cadmium concentration 26 mg/L, the dosage of waste Saccharomyces cerevisiae 16.25 g/L, temperature 18 ℃, pH 6.0 and precipitation time 4 h. Biosorption-precipitation method is effective to remove cadmium in cadmium-containing electroplating wastewater by waste Saccharomyces cerevisiae. The SEM, infrared spectroscopy and Zeta-potential of the cells show that chemical chelating is the main adsorption form; electrostatic attraction, hydrogen bonding and van der Waals force all function in adsorption process; and ―NH2―,―C=O―,―C=O―NH―,―CH3, ―OH are the main adsorption groups.
Wengang Liu - One of the best experts on this subject based on the ideXlab platform.
-
Removing cadmium from electroplating wastewater by waste Saccharomyces cerevisiae
Transactions of Nonferrous Metals Society of China, 2008Co-Authors: Shu-juan Dai, Dezhou Wei, Dong-qin Zhou, Chunyun Jia, Yu-juan Wang, Wengang LiuAbstract:The appropriate condition and scheme of removing cadmium from electroplating wastewater were investigated by adsorption-precipitation method using waste Saccharomyces cerevisiae(WSC) as sorbent. Effect factors on biosorption of cadmium in cadmium-containing electroplating wastewater by waste Saccharomyces cerevisiae and precipitation process of waste Saccharomyces cerevisiae after adsorbing cadmium were studied. The results show that removal rate of cadmium is over 88% after 30 min adsorbing under the condition of cadmium concentration 26 mg/L, the dosage of waste Saccharomyces cerevisiae 16.25 g/L, temperature 18 ℃, pH 6.0 and precipitation time 4 h. Biosorption-precipitation method is effective to remove cadmium in cadmium-containing electroplating wastewater by waste Saccharomyces cerevisiae. The SEM, infrared spectroscopy and Zeta-potential of the cells show that chemical chelating is the main adsorption form; electrostatic attraction, hydrogen bonding and van der Waals force all function in adsorption process; and ―NH2―,―C=O―,―C=O―NH―,―CH3, ―OH are the main adsorption groups.
Chang Hwan Choi - One of the best experts on this subject based on the ideXlab platform.
-
Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçet’s Disease Patients: Relation to Clinical Course
Diseases of the Colon & Rectum, 2006Co-Authors: Chang Hwan Choi, Sung Jae ShinAbstract:Purpose This study was designed to assess anti- Saccharomyces cerevisiae antibody positive rate in Behçet’s disease and intestinal Behçet’s disease and to evaluate whether anti- Saccharomyces cerevisiae antibody expression is associated with clinical findings at diagnosis and clinical course of intestinal Behçet’s disease. Methods One hundred six patients with intestinal Behçet’s disease, 30 patients with Behçet’s disease, and 45 healthy control subjects were included. Anti- Saccharomyces cerevisiae antibody was detected by indirect immunofluorescence assay. According to anti- Saccharomyces cerevisiae antibody expression, the various parameters at diagnosis, cumulative relapse rates, and cumulative probabilities of operation were analyzed. Results Anti- Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet’s disease, 3.3 percent in Behçet’s disease, and 8.8 percent in healthy control subjects. In patients with intestinal Behçet’s disease, age, gender, distribution of Behçet’s disease subtype, symptoms, laboratory tests, and colonoscopic findings at diagnosis were not different according to anti- Saccharomyces cerevisiae antibody expression. Cumulative probability of a first operation was significantly higher in anti- Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease than in anti- Saccharomyces cerevisiae antibody (−) intestinal Behçet’s disease: 44.8 and 17.2 percent at one year, and 53 and 24.3 percent at two years after diagnosis, respectively ( P = 0.006). The number of patients who underwent two or more operations was higher in anti- Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease than in anti- Saccharomyces cerevisiae antibody (−) intestinal Behçet’s disease (21.3 vs . 8.5 percent). The cumulative relapse rates were not different between the two groups. Conclusions Anti- Saccharomyces cerevisiae antibody positive rate was 44.3 percent in intestinal Behçet’s disease. Clinical findings at diagnosis and cumulative relapse rates of intestinal Behçet’s disease were not found to be associated with anti- Saccharomyces cerevisiae antibody expression. However, patients with anti- Saccharomyces cerevisiae antibody (+) intestinal Behçet’s disease were more likely to receive surgical treatment.
Pierre Desreumaux - One of the best experts on this subject based on the ideXlab platform.
-
A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome
Digestive and Liver Disease, 2015Co-Authors: Guillaume Pineton De Chambrun, Amélie Chau, Fanny Pelerin, Peter Justen, Murielle Cazaubiel, Christel Neut, Pierre DesreumauxAbstract:Background: We aimed to evaluate clinical symptoms in subjects with irritable bowel syndrome receiving Saccharomyces cerevisiae in a randomized double-blind placebo-controlled clinical trial. Methods: Overall, 179 adults with irritable bowel syndrome (Rome III criteria) were randomized to receive once daily 500. mg of Saccharomyces cerevisiae, delivered by one capsule (n= 86, F: 84%, age: 42.5 ± 12.5), or placebo (n= 93, F: 88%, age: 45.4 ± 14) for 8 weeks followed by a 3-week washout period. After a 2-week run-in period, cardinal symptoms (abdominal pain/discomfort, bloating/distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily and assessed each week. A safety assessment was carried out throughout the study. Results: The proportion of responders, defined by an improvement of abdominal pain/discomfort, was significantly higher (p= 0.04) in the treated group than the placebo group (63% vs 47%, OR = 1.88, 95%, CI: 0.99-3.57) in the last 4 weeks of treatment. A non-significant trend of improvement was observed with Saccharomyces cerevisiae for the other symptoms. Saccharomyces cerevisiae was well tolerated and did not affect stool frequency and consistency. Conclusion: Saccharomyces cerevisiae is well tolerated and reduces abdominal pain/discomfort scores without stool modification. Thus, Saccharomyces cerevisiae may be a new promising candidate for improving abdominal pain in subjects with irritable bowel syndrome.
